Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Patients with IBD not receiving optimal care

A study in the latest American Journal of Gastroenterology shows that patients with IBD often do not receive optimal medical therapy that includes failure to use steroid-sparing agents, and inadequate screening for colorectal cancer.

News image

fiogf49gjkf04

Guidelines have been published as a framework for therapy of patients with inflammatory bowel disease (IBD).

Dr Sarathchandra and colleagues from Massachusetts determined whether patients referred for a second opinion were receiving therapy in accordance with practice guidelines.

9 of 12 patients with distal ulcerative colitis were not receiving rectal aminosalicylate therapy
American Journal of Gastroenterology

The researchers enrolled 67 patients with luminal IBD.

The team reported that patients were under the care of a gastroenterologist who sought a second opinion at Brigham and Women's Hospital between 2001 and 2003.

The researchers obtained clinical information by direct patient interview at the time of initial patient visit and by a review of prior records.

The team's data included the diagnosis, clinical symptoms, prior medical therapy, preventive measures for metabolic bone disease, and colon-cancer screening.

The study population consisted of 21 with ulcerative colitis, 44 with Crohn's disease and 2 in whom the diagnosis of IBD could not be confirmed.

Of the 65 patients with confirmed IBD, the researchers noted that 56 patients had symptoms of active disease and 9 were asymptomatic.

All analyses were carried out on the 56 patients with active disease.

Of the 33 patients treated with aminosalicylates, the researchers reported that 21 were not receiving maximal doses.

The research team found that 9 of 12 patients with distal ulcerative colitis were not receiving rectal aminosalicylate therapy.

Within 6 months of their clinic visit, 35 patients had received corticosteroid therapy.

The team observed that 27 patients had been treated with corticosteroids for greater than 3 months.

The research team found that in 16 of 27 there was no attempt to start steroid sparing medications such as 6-mercaptopurine, azathioprine, or infliximab.

Of the 11 patients treated with either 6-mercaptopurine or azathioprine, 9 were suboptimally dosed without an attempt to increase dosage.

In addition, the team noted that of the 27 patients on prolonged corticosteroid therapy 21 received inadequate treatment to prevent metabolic bone disease.

The researchers also observed that 3 of 9 patients meeting indications for surveillance colonoscopy for dysplasia, had not undergone colonoscopy at the appropriate interval.

Dr Sarathchandra's team concluded, “Patients with IBD often do not receive optimal medical therapy.”

“In particular, there is suboptimal dosing of 5-ASA and immunomodulatory medications, and prolonged use of corticosteroids.”

“There is also failure to use steroid-sparing agents, inadequate measures to prevent metabolic bone disease, and inadequate screening for colorectal cancer.”

Am J Gastroenterol 2005: 100(6): 1357
14 June 2005

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us